Skip to main content
Premium Trial:

Request an Annual Quote

Pairings: Apr 13, 2011

Premium

Roche Diagnostics has appointed Robert Yates to be the new Head of Roche Applied Science, a position he will take over from Manfred Baier, who will be retiring from the company at the end of the year. Yates formerly was global head of business development and licensing at Roche Diagnostics.


The Critical Path Institute is searching for a new CEO. Recently, C-Path Institute Founder Raymond Woosley said he would step down as president/CEO of the institute in January 2012 or as soon as the position had been filled.

A search committee formed by the Board of Directors announced this week that they are actively looking for Woosley's replacement. The new leader will be tasked with working collaboratively with regulatory and industry leaders to advance research and speed the introduction of innovative treatments to market.

C-Path is asking its collaborators and consortia members to recommend candidates for the position. People interested in applying for this position should send a letter of interest, CV, and three references to searchcommittee [at] c-path [.] org.

The Scan

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.

Study Reveals Potential Sex-Specific Role for Noncoding RNA in Depression

A long, noncoding RNA called FEDORA appears to be a sex-specific regulator of major depressive disorder, affecting more women, researchers report in Science Advances.

New mRNA Vaccines Offer Hope for Fighting Malaria

A George Washington University-led team has developed mRNA vaccines for malaria that appear to provide protection in mice, as they report in NPJ Vaccines.

Unique Germline Variants Found Among Black Prostate Cancer Patients

Through an exome sequencing study appearing in JCO Precision Oncology, researchers have found unique pathogenic or likely pathogenic variants within a cohort of Black prostate cancer patients.